Antinociceptive effect of oxycodone in diabetic mice.

[1]  L. Plaghki,et al.  Critical review of oral drug treatments for diabetic neuropathic pain—clinical outcomes based on efficacy and safety data from placebo‐controlled and direct comparative studies , 2005, Diabetes/metabolism research and reviews.

[2]  J. Kamei,et al.  Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. , 2004, Journal of pharmacological sciences.

[3]  H. Pan,et al.  Antinociceptive Effect of Morphine, but not &mgr; Opioid Receptor Number, Is Attenuated in the Spinal Cord of Diabetic Rats , 2003, Anesthesiology.

[4]  J. Lakoski,et al.  Functional &mgr; Opioid Receptors Are Reduced in the Spinal Cord Dorsal Horn of Diabetic Rats , 2002, Anesthesiology.

[5]  S. Tanaka,et al.  Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. , 2001, European journal of pharmacology.

[6]  J. Kamei,et al.  Antinociceptive effect of U‐50488H, a κ‐opioid agonist, in streptozotocin‐induced diabetic mice , 2001 .

[7]  C. Nielsen,et al.  Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  M. Ohsawa,et al.  Effects of a μ-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice , 2000 .

[9]  M. Ohsawa,et al.  The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. , 2000, European journal of pharmacology.

[10]  P. Khosla,et al.  Differential modulation of nociceptive responses to mu and kappa opioid receptor directed drugs by blood glucose in experimentally induced diabetes rats. , 2000, Indian journal of experimental biology.

[11]  M. Ohsawa,et al.  Role of intracellular calcium in thermal allodynia and hyperalgesia in diabetic mice , 1999, Brain Research.

[12]  F. Gries,et al.  Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[13]  B. Bauduceau,et al.  Added benfluorex in obese insulin-requiring type 2 diabetes. , 1998, Diabetes & metabolism.

[14]  M. Ohsawa,et al.  Possible involvement of protein kinase C in the attenuation of [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced antinociception in diabetic mice. , 1997, European journal of pharmacology.

[15]  Maree T. Smith,et al.  The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated , 1997, Pain.

[16]  J. Kamei,et al.  Supraspinal δ1-opioid receptor-mediated antinociceptive properties of (-)-TAN-67 in diabetic mice , 1997 .

[17]  M. Misawa,et al.  Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  M. Misawa,et al.  Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice , 1995 .

[19]  J. Wright,et al.  Review of the Symptomatic Treatment of Diabetic Neuropathy , 1994, Pharmacotherapy.

[20]  M. Misawa,et al.  Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. , 1994, Research communications in chemical pathology and pharmacology.

[21]  M. Misawa,et al.  Streptozotocin-induced diabetes selectively reduces antinociception mediated by μ 1-opioid receptors, but not that mediated by μ 2-opioid receptors , 1994, Neuroscience Letters.

[22]  M. Misawa,et al.  Streptozotocin-induced diabetes selectively enhances antinociception mediated by δ1-but not δ2-opioid receptors , 1994 .

[23]  A. Gulati,et al.  Prazosin blocks the pressor but not the regional circulatory effects of diaspirin crosslinked hemoglobin. , 1994, Life sciences.

[24]  J. Kamei,et al.  Role of spleen or spleen products in the deficiency in morphine-induced analgesia in diabetic mice , 1992, Brain Research.

[25]  T. Endoh,et al.  Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. , 1992, Archives internationales de pharmacodynamie et de therapie.

[26]  J. Kamei,et al.  Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists , 1992, Brain Research.

[27]  A. Somogyi,et al.  Mu receptor binding of some commonly used opioids and their metabolites. , 1991, Life sciences.

[28]  E. Kalso,et al.  Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. , 1990, Pharmacology & toxicology.

[29]  W. Dewey,et al.  Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. , 1981, The Journal of pharmacology and experimental therapeutics.

[30]  R. Houde,et al.  Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. , 1978, The Journal of pharmacology and experimental therapeutics.

[31]  R. Houde,et al.  Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. , 1978, The Journal of pharmacology and experimental therapeutics.

[32]  Fred E. D'Amour,et al.  A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .